A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer.
Fifteen patients with recurrent squamous cell head and neck cancer were treated with deoxyspergualin. There were no objective responses in 14 evaluable patients. The most common toxicity was reversible hypotension, which prompted dose reduction in nine patients. Deoxyspergualin is not recommended for the treatment of squamous cell head and neck cancer.
Pfister
D G
DG
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Bajorin
D
D
Motzer
R J
RJ
Scher
H
H
Louison
C
C
Harrison
L
L
Shah
J
J
Strong
E
E
Bosl
G
G
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006146:Guanidines / Q000009:adverse effects / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D015507:Drugs, Investigational; D006146:Guanidines; C037258:gusperimus